Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
8 evidence topics · 7 sources
Time to maximum concentration and half-life in the phase 1 dose escalation
“Maximal concentrations (Cmax) were generally reached between 2 and 5 hours after the start of infusion on cycle 1 day 1. Thereafter, the concentration–time profiles declined in a biexponential manner at higher doses, with geometric mean half-life ranging from 14 hours for lower doses associated with target-mediated drug disposition to 84 hours for higher doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company-reported half-life of about eight days
Dose proportionality and target-mediated drug disposition
“Cmax and area under the plasma concentration versus time curve from 0 to 168 hours (AUC0–168h) increased in a slightly more than dose-proportional manner between 64 and 500 mg. However, a nearly dose-proportional increase in Cmax and AUC0–168h was observed between 500 and 1,500 mg. These data suggest that nonlinear clearance is negligible and linear clearance dominates at doses above 500 mg as EGFR is likely fully saturated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, ficerafusp alfa showed a nonlinear PK profile consistent with target-mediated drug disposition at doses <500 mg. Specifically, nonoverlapping exposures were achieved at 750 and 1,500 mg once weekly dosages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity
Nonclinical pharmacokinetics in cynomolgus monkeys
“Following a single intravenous infusion of BCA101 to cynomolgus monkeys, serum mean maximum concentrations and mean exposures of the molecule increased dose proportionally (Supplementary Fig. S17), with no saturation of the routes of elimination. The observed volumes of distribution (33–74 mL/kg) suggest that BCA101 is well distributed to the tissues. Half-life of BCA101 ranged from 12.9 to 84.5 hours for the doses tested.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-selection rationale for 1500 mg weekly
“As a result, ficerafusp alfa 1,500 mg once weekly was selected as the recommended dosage based on the PK, pharmacodynamic, and preliminary antitumor activity observed at this dosage level and will continue to be assessed for safety and efficacy during dose expansion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic basis for less frequent dosing regimens
“Based on available PK results from 1,500 to 1,750-mg every-2-week cohorts, the every-2-week dosing regimen is expected to reach non–clinically derived target concentrations (Supplementary Fig. S2A and S2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote